Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

546
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
546
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

674
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
674
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.3K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

508
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
508
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

358
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
358
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

593
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
593

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted Preoperative Nutritional Support within an Enhanced Recovery After Surgery Program for Malnourished Colorectal Cancer Patients: Postoperative Outcomes Comparable to Well-Nourished Patients in a Prospective Single-Center Cohort.

Annals of surgical oncology·2026
Same author

Exploring the Socioeconomic Factors Affecting the Care of Pediatric Hidradenitis Suppurativa Patients: A Retrospective Single-Center Study.

Pediatric dermatology·2025
Same author

Molecular simulations meet personalized medicine: The mechanism of action of CLC-5 antiporter and the origin of Dent's disease.

PNAS nexus·2025
Same author

PRKG1 hinders myogenic differentiation and predicts response to AKT inhibitor ipatasertib in Rhabdomyosarcoma.

Nature communications·2025
Same author

Optimizing drug design by merging generative AI with a physics-based active learning framework.

Communications chemistry·2025
Same author

Reliability of the Ichthyosis Scoring System in Individuals With Skin of Color.

JAMA dermatology·2025

Related Experiment Video

Updated: Feb 26, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

23.0K

Diffuse Hepatic Hemangiomas Successfully Treated Using Sirolimus and High-Dose Propranolol.

Donald Warren1, Lucia Diaz2, Moise Levy2

  • 1Baylor Scott & White, Marble Falls, Texas.

Pediatric Dermatology
|July 22, 2017
PubMed
Summary

Diffuse hepatic hemangiomas are a serious condition. This case study shows sirolimus and high-dose propranolol can effectively treat infants with this condition when initial therapies fail.

More Related Videos

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
05:30

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach

Published on: August 8, 2025

628
A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.8K

Related Experiment Videos

Last Updated: Feb 26, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

23.0K
Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
05:30

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach

Published on: August 8, 2025

628
A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.8K

Area of Science:

  • Pediatric Gastroenterology
  • Vascular Anomalies

Background:

  • Diffuse hepatic hemangiomas are rare, potentially life-threatening vascular tumors in infants.
  • Management is challenging, often requiring multi-modal approaches.

Observation:

  • An infant presented with diffuse hepatic hemangiomas unresponsive to first-line treatments.
  • The infant's condition was critical, posing significant health risks.

Findings:

  • Treatment with sirolimus demonstrated significant efficacy.
  • High-dose propranolol, in conjunction with sirolimus, led to a positive clinical response.

Implications:

  • Sirolimus and high-dose propranolol represent a promising therapeutic strategy for refractory diffuse hepatic hemangiomas.
  • This case highlights potential treatment options for severe infantile liver vascular tumors.